Small Molecule · STX209
Arbaclofen
Arbaclofen (STX209; R-baclofen) is the single R-enantiomer of the racemic muscle relaxant baclofen and a selective agonist of the GABA-B receptor. It is roughly 5-fold more potent than racemic baclofen, with 100- to 1000-fold greater GABA-B specificity than the S-enantiomer. It has been studied in two separate lines of development. The neurodevelopmental line started with Seaside Therapeutics (STX209) in fragile X syndrome and autism. Its Phase 2 and Phase 3 trials missed their primary endpoints, and Seaside stopped development in 2013. Allos Pharma (Cambridge, MA) licensed the fragile X program in 2020, added autism in 2023, and announced worldwide rights in 2025. Academic consortia (AIMS-2-TRIALS in Europe, the POND network in Canada) have kept testing it in autistic children; AIMS-2-TRIALS-CT1 missed its primary endpoint (Vineland Socialization) but favoured arbaclofen on several secondary measures. Separately, Osmotica/RVL Pharmaceuticals developed an extended-release tablet for multiple sclerosis spasticity, which received an FDA Complete Response Letter in December 2020. Arbaclofen is not approved anywhere.
Also known as: STX209, STX-209, arbaclofen, R-baclofen, (R)-baclofen, OS440, 69308-37-8, (3R)-4-amino-3-(4-chlorophenyl)butanoic acid
Key facts
- Modality
- Small molecule
- Chemical class
- GABA analogue, amino acid, chloroarene
- Chemistry
- Single enantiomer
- Mechanism
- GABA-B receptor agonist
- Highest phase
- Phase 3
- Lead indication
- Autism spectrum disorder
- Developer
- Seaside Therapeutics, Inc.
- Designations
- FDA Orphan Drug Designation (Fragile X Syndrome), Per Allos Pharma'S 2023-09-18 Release; Grant Date Not Disclosed, FDA Orphan Drug Designation (Alleviation Of Signs And Symptoms Of Spasticity Resulting From Multiple Sclerosis), Per Osmotica/RVL 10-K Filings; Grant Date Not Disclosed
- Trials
- 14 tracked · 1 recruiting · 239 sites
- Next catalyst
- December 2026 — Registry results (Autism spectrum disorder)
Mechanism of action#
Selective orthosteric agonist of the GABA-B receptor, a Gi/o-coupled class C GPCR that works as a GABAB1/GABAB2 heterodimer; the agonist binds the GABAB1 subunit. Arbaclofen is the active R-enantiomer of baclofen, with 100- to 1000-fold greater GABA-B specificity than the S-enantiomer and about 5-fold greater potency than racemic baclofen. In the neurodevelopmental programs, the hypothesis is that GABA-B activation rebalances cortical excitation and inhibition and dampens excess glutamate release, which is implicated in fragile X syndrome (Fmr1 knockout models) and some autism. In spasticity, the effect comes from presynaptic inhibition of spinal reflexes, as with baclofen.
| Target | Action | Affinity |
|---|---|---|
| GABA-B receptorprimaryGABBR1 | Agonist | —ⓘ |
Formulations#
| Formulation | Route | Regimen | Pharmacokinetics |
|---|---|---|---|
| Arbaclofen extended-release tablets (Osmodex), 40 or 80 mg/day BIDOsmodex osmotic extended-release tablet Arbaclofen ER 40 mg/day or 80 mg/day in two daily doses (12-hour dosing interval) in the Phase 3 OS440-3004 study (NCT03290131). The planned OS440-3006 study (NCT05179577) uses 80 mg/day, twice daily. | Oral | Twice daily | — |
| Arbaclofen oral (orally disintegrating) tablets, 5-20 mg BID-TID AIMS-2-TRIALS-CT1 (NCT03682978): orally disintegrating tablets of 5, 10, 15 and 20 mg, flexibly titrated over 5 weeks and stratified by age. Ages 5-11 went from 5 mg BID up to 15 mg TID; ages 12-17 went from 5 mg QD up to 20 mg TID. Treatment lasted 16 weeks. The Canadian ARBA trial (NCT03887676) used the same orally disintegrating tablet strengths. | Oral | Three times daily | — |
Development timeline#
- UpcomingClinicalTrials.gov estimated primary completion of Phase 3 OS440-3006 (NCT05179577), arbaclofen ER 80 mg/day vs placebo in MS spasticity: January 2028. The study is not yet recruiting, with an estimated January 2027 start.Multiple sclerosis
- FDA regulatory meeting / outcomeAllos reports FDA alignment on a confirmatory Phase 3 design for arbaclofen in fragile XFragile X syndrome↗
- RVL Pharmaceuticals' FY2022 10-K says it is looking to sell or out-license arbaclofen ER tablets. No later disclosure of the program's owner or status was found.Multiple sclerosis↗
- FDA regulatory meeting / outcomeFDA declines to agree a Special Protocol Assessment for a new arbaclofen ER studyMultiple sclerosis↗
- FDA Complete Response Letter, which recommends a new study to provide substantial evidence of efficacy. The program reverts to a Phase 3 requirement.Multiple sclerosis↗
- Complete Response LetterFDA issues a Complete Response Letter for arbaclofen ER in MS spasticityMultiple sclerosis↗
- Allos Pharma announces exclusive license rights to arbaclofen in fragile X syndrome and says it plans to take it through NDA approval.Fragile X syndrome↗
- missedPhase 3 209FX301 (adolescents/adults aged 12-50, flexible dose, 125 randomised): no benefit of arbaclofen over placebo on any measure, including the primary ABC-CFX Social Avoidance subscale.Fragile X syndrome↗
- missedPhase 3 209FX302 (children aged 5-11, 172 randomised, fixed doses): missed the primary ABC-CFX Social Avoidance endpoint. The 10 mg TID group beat placebo on ABC-CFX Irritability (p=0.03) and the Parenting Stress Index (p=0.03), with trends on Social Avoidance and Hyperactivity.Fragile X syndrome↗
- Phase 3 OS440-3002 (NCT01743651) of arbaclofen tablets 40 mg/day vs baclofen and placebo in MS spasticity starts.Multiple sclerosis
- missedPhase 2 crossover of STX209 in 63 FXS subjects: no difference from placebo on the primary ABC-Irritability endpoint; post hoc benefit on ABC Social Avoidance and, in the more socially impaired subgroup, on Vineland-II Socialization.Fragile X syndrome↗
- Phase 3 child study 209FX302 (NCT01325220; fixed doses, ages 5-11) starts; the adolescent/adult Phase 3 209FX301 (NCT01282268) runs in parallel.Fragile X syndrome
- UpcomingClinicalTrials.gov estimated primary completion of AIMS-2-CT2 (NCT07655115), the arbaclofen shiftability biomarker study in autistic children and adolescents: December 2026.Autism spectrum disorder
- missedAIMS-2-TRIALS-CT1 (122 ITT, ages 5-17, 16 weeks): no significant effect on the primary Vineland Socialization endpoint or the prespecified key secondary outcomes. All secondary endpoints favoured arbaclofen, with significant improvements on SRS-2, AIM total, some ABC subscales and quality of life. Sleep problems were more frequent on arbaclofen (57.6% vs 34.9%).Autism spectrum disorder↗
- AIMS-2-CT2 (NCT07655115) starts: a single-dose crossover biomarker study followed by 10 weeks of open-label treatment. It is registered as Phase 3 but is not a confirmatory efficacy trial.Autism spectrum disorder
- FinancingAllos Pharma receives a non-dilutive Simons Foundation grant for arbaclofen in autismAutism spectrum disorder↗
- Allos Pharma announces worldwide exclusive rights to granted patents and clinical programs for arbaclofen in further indications, including autism spectrum disorder.Autism spectrum disorder↗
- Licensing dealAllos Pharma obtains worldwide rights to arbaclofen in autism spectrum disorderAutism spectrum disorder↗
- missedCanadian ARBA trial (POND network) of arbaclofen vs placebo for 16 weeks in autistic children and teens aged 5-17: the Vineland social primary outcome improved but not significantly vs placebo; parent ratings showed gains in some secondary measures.Autism spectrum disorder↗
- Academic development restarts: the Canadian ARBA trial (NCT03887676, Holland Bloorview / POND network) starts, followed by AIMS-2-TRIALS-CT1 (NCT03682978) on 2019-09-19.Autism spectrum disorder
- missedSeaside Phase 2 of arbaclofen in autism (150 participants aged 5-21): no difference from placebo on the primary ABC Social Withdrawal/Lethargy subscale; a prespecified secondary analysis showed improvement on CGI-Severity.Autism spectrum disorder↗
- Seaside open-label extension 209AS209 (NCT01706523) registered as terminated, with primary completion July 2013. Sponsor development of arbaclofen in autism stopped.Autism spectrum disorder
- Trial terminatedSeaside terminates the open-label extension of STX209 in autismAutism spectrum disorder
- Seaside starts the randomised, placebo-controlled Phase 2 209AS208 (NCT01288716; 150 participants aged 5-21). Primary endpoint: ABC Social Withdrawal/Lethargy.Autism spectrum disorder
- Seaside Therapeutics opens study 22003 (NCT00846547), an open-label, flexible-dose Phase 2 of STX209 in autism spectrum disorder.Autism spectrum disorder
- Seaside Therapeutics starts Phase 2 study 22001 (NCT00788073): a placebo-controlled crossover trial of STX209 in 63 subjects with fragile X syndrome.Fragile X syndrome
- Osmotica resubmits the arbaclofen ER NDA (first submitted in 2015) for spasticity in multiple sclerosis. FDA accepts it as a complete response to its 2016-07-09 action letter and sets a 2020-12-29 goal date.Multiple sclerosis↗
Arbaclofen for Autism spectrum disorder#
Phase 2ActiveAutism spectrum disorder indication →
Arbaclofen, a selective GABA-B receptor agonist, for social function and core symptoms in autistic children and adolescents. The idea is that boosting GABA-B inhibition rebalances cortical excitation and inhibition. Seaside Therapeutics' Phase 2 (209AS208, NCT01288716; 150 participants aged 5-21) missed its primary endpoint (ABC Social Withdrawal/Lethargy) but improved clinician-rated CGI-Severity. Seaside stopped development in 2013, and its open-label extension was terminated.
Readouts
- December 2026AnticipatedRegistry resultsNCT07655115
ClinicalTrials.gov estimated primary completion of AIMS-2-CT2 (NCT07655115), the arbaclofen shiftability biomarker study in autistic children and adolescents: December 2026.
- 2026-01-22ReportedFull resultsmissedNCT03682978
AIMS-2-TRIALS-CT1 (122 ITT, ages 5-17, 16 weeks): no significant effect on the primary Vineland Socialization endpoint or the prespecified key secondary outcomes. All secondary endpoints favoured arbaclofen, with significant improvements on SRS-2, AIM total, some ABC subscales and quality of life. Sleep problems were more frequent on arbaclofen (57.6% vs 34.9%). ↗
- 2023-05-05ReportedTopline datamissedNCT03887676
Canadian ARBA trial (POND network) of arbaclofen vs placebo for 16 weeks in autistic children and teens aged 5-17: the Vineland social primary outcome improved but not significantly vs placebo; parent ratings showed gains in some secondary measures. ↗
- 2016-10-17ReportedFull resultsmissedNCT01288716
Seaside Phase 2 of arbaclofen in autism (150 participants aged 5-21): no difference from placebo on the primary ABC Social Withdrawal/Lethargy subscale; a prespecified secondary analysis showed improvement on CGI-Severity. ↗
Arbaclofen for Fragile X syndrome#
Phase 3ActiveFragile X syndrome indication →
Arbaclofen (STX209), a selective GABA-B receptor agonist, for social avoidance and behavioural symptoms of fragile X syndrome (FXS). The rationale comes from Fmr1 knockout models, where arbaclofen reversed disease-related pathology. Seaside Therapeutics' Phase 2 crossover trial (NCT00788073; 63 subjects aged 6-39) missed its primary irritability endpoint, though a post hoc analysis showed benefit on ABC Social Avoidance. Two Phase 3 trials followed. The adolescent/adult trial 209FX301 (NCT01282268; 125 subjects) showed no benefit on any measure. The child trial 209FX302 (NCT01325220; 172 children aged 5-11) missed the Social Avoidance primary endpoint, but the highest dose (10 mg TID) separated from placebo on ABC Irritability and the Parenting Stress Index. Seaside terminated the open-label extension in May 2013, citing resource limitations. Allos Pharma, founded by Seaside's founders, licensed arbaclofen for FXS in November 2020. In 2023 it said it had reached alignment with the FDA and the fragile X community on a confirmatory Phase 3 design, and it lists an FDA orphan designation in FXS. No new FXS trial is registered on ClinicalTrials.gov as of 2026-10-28. Mirum Pharmaceuticals' FY2025 10-K still lists Allos's arbaclofen among FXS programs in clinical development.
Readouts
- 2017-06-12ReportedFull resultsmissedNCT01282268
Phase 3 209FX301 (adolescents/adults aged 12-50, flexible dose, 125 randomised): no benefit of arbaclofen over placebo on any measure, including the primary ABC-CFX Social Avoidance subscale. ↗
- 2017-06-12ReportedFull resultsmissedNCT01325220
Phase 3 209FX302 (children aged 5-11, 172 randomised, fixed doses): missed the primary ABC-CFX Social Avoidance endpoint. The 10 mg TID group beat placebo on ABC-CFX Irritability (p=0.03) and the Parenting Stress Index (p=0.03), with trends on Social Avoidance and Hyperactivity. ↗
- 2012-09-19ReportedFull resultsmissedNCT00788073
Phase 2 crossover of STX209 in 63 FXS subjects: no difference from placebo on the primary ABC-Irritability endpoint; post hoc benefit on ABC Social Avoidance and, in the more socially impaired subgroup, on Vineland-II Socialization. ↗
Arbaclofen for Multiple sclerosis#
Phase 3UnknownMultiple sclerosis indication →
Arbaclofen extended-release tablets (Osmotica's Osmodex osmotic tablet, OS440) for spasticity in multiple sclerosis. This is a neurology program, not the lead, recorded for completeness. The first Phase 3 (OS440-3002, NCT01743651; arbaclofen 40 mg/day vs baclofen 80 mg/day vs placebo) was completed in 2014. According to Osmotica, an FDA audit then judged that trial's data insufficient to support a marketing application. The second Phase 3 (OS440-3004, NCT03290131; 536 patients, 40 or 80 mg/day for 12 weeks) significantly reduced TNmAS-MAL spasticity at 40 mg/day vs placebo (LS mean difference -0.39) but missed the co-primary CGIC endpoint. The NDA, first filed in 2015, was resubmitted in June 2020 with a 2020-12-29 goal date. FDA issued a Complete Response Letter on 2020-12-28: it found the statistical analysis of the 40 mg TNmAS-MAL co-primary endpoint inadequately justified and recommended a new study. A Type A meeting followed (2021-03-04), and a Special Protocol Assessment for a further trial was not agreed (FDA letter 2021-10-15). A new Phase 3 (OS440-3006, NCT05179577; 80 mg/day BID, 442 planned) is registered as not yet recruiting, with a January 2027 start. In its FY2022 10-K, RVL Pharmaceuticals said it was looking to sell or out-license arbaclofen ER. No later owner or development decision could be cited, so status is unknown.
Readouts
- January 2028AnticipatedRegistry resultsNCT05179577
ClinicalTrials.gov estimated primary completion of Phase 3 OS440-3006 (NCT05179577), arbaclofen ER 80 mg/day vs placebo in MS spasticity: January 2028. The study is not yet recruiting, with an estimated January 2027 start.
Clinical trials#
NCT05179577OS440-3006Phase 3Activen=442
A Randomized, Double-Blind, Placebo-Controlled Parallel Group Study to Investigate the Safety and Efficacy of Arbaclofen Extended-Release Tablets for the Treatment of Spasticity in Patients With Multiple Sclerosis (Study OS440-3006)
NCT07655115AIMS-2-CT2Phase 3Recruitingn=103
A Follow-Up Shiftability Study of Arbaclofen With an Open-Label Extension for the Study of Biomarkers in Children and Adolescents With Autism Spectrum Disorders.
SpainFrance
NCT03682978AIMS2-CT-01Phase 2Completedn=124
A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Arbaclofen Administered for the Treatment of Social Function in Children and Adolescents With Autism Spectrum Disorders
United KingdomSpainFrance
NCT03887676ARB-05-2018Phase 2Completedn=90
A Randomized Placebo-controlled Trial of ARBaclofen vs. Placebo in the Treatment of Children and Adolescents With ASD
Canada
NCT03319732OS440-3005Phase 3Completedn=323
An Open-Label Study to Evaluate the Long-Term Safety of Arbaclofen Extended-Release Tablets in Multiple Sclerosis Patients With Spasticity (Study OS440-3005)
United States
Show all 14 trials
NCT03290131OS440-3004Phase 3Completedn=536
A Randomized, Double-Blind, Placebo-Controlled Parallel Group Study to Investigate the Safety and Efficacy of Arbaclofen Extended-Release Tablets for the Treatment of Spasticity in Patients With Multiple Sclerosis
PolandBulgariaBelarusCroatia
NCT01743651OS440-3002Phase 3Completedn=353
A Randomized, Double-Blind, Parallel Group Study to Compare the Safety and Efficacy Arbaclofen ER Tablets to Placebo and Baclofen Tablets, USP for the Treatment of Spasticity in Patients With Multiple Sclerosis
United StatesUkraineRussia
NCT01706523209AS209Phase 3Discontinuedn=165
An Open-Label Extension Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of STX209 (Arbaclofen) in Subjects With Autism Spectrum Disorders
United States
NCT01555333209FX303Phase 3Discontinuedn=357
An Open-Label Extension Study to Evaluate the Safety, Tolerability, and Pharmacokinetics in Subject With Fragile X Syndrome
United States
NCT01325220209FX302Phase 3Completedn=172
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Function in Children With Fragile X Syndrome
United States
NCT01282268209FX301Phase 3Completedn=125
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Function in Adolescents and Adults With Fragile X Syndrome
United States
NCT01288716209AS208Phase 2Completedn=150
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
United States
NCT0084654722003Phase 2Completedn=32
An Open-Label, Flexible-Dose Evaluation of the Safety and Tolerability of STX209 for Treatment of Irritability in Subjects With Autism Spectrum Disorders
United States
NCT0078807322001Phase 2Completedn=63
A Double-Blind, Placebo-Controlled, Crossover, Flexible-Dose Evaluation of the Efficacy, Safety and Tolerability of STX209 in the Treatment of Irritability in Subjects With Fragile X Syndrome
United States
Conference coverage#
STX209 appears in 1 CNS Pulse conference abstract:
Sources#
- Allos Pharma Acquires Global Rights to Arbaclofen, Reports Positive ASD Trial Results and Grant Award (2025-08-21, PR Newswire wire copy) — Allos Pharma Inc. (via The AI Journal)
- Allos Pharma Inc. Expands Intellectual Property Rights for Arbaclofen (2023-09-18, PR Newswire wire copy) — Allos Pharma Inc. (via BioSpace)
- Allos Pharma secures exclusive license on arbaclofen in Fragile X Syndrome (2020-11-19, wire copy) — Allos Pharma Inc. (via BioSpace)
- Berry-Kravis E, et al. Arbaclofen in fragile X syndrome: results of phase 3 trials. J Neurodev Disord 2017;9:3 — Journal of Neurodevelopmental Disorders / PubMed
- Berry-Kravis EM, et al. Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial. Sci Transl Med 2012;4(152):152ra127 — Science Translational Medicine / PubMed
- NCT00788073 (22001) — Safety, Tolerability and Efficacy Study of STX209 in Subjects With Fragile X Syndrome — ClinicalTrials.gov (U.S. National Library of Medicine)
- NCT00846547 (22003) — Open-Label Study of the Safety and Tolerability of STX209 in Subjects With Autism Spectrum Disorders — ClinicalTrials.gov (U.S. National Library of Medicine)
- NCT01282268 (209FX301) — Efficacy and Safety Study of STX209 (Arbaclofen) for Social Withdrawal in Adolescents and Adults With Fragile X Syndrome — ClinicalTrials.gov (U.S. National Library of Medicine)
- NCT01288716 (209AS208) — Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders — ClinicalTrials.gov (U.S. National Library of Medicine)
- NCT01325220 (209FX302) — Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome — ClinicalTrials.gov (U.S. National Library of Medicine)
Show all 26 sources
- NCT01555333 (209FX303) — An Open Label Extension Study in Subjects With Fragile X Syndrome — ClinicalTrials.gov (U.S. National Library of Medicine)
- NCT01706523 (209AS209) — Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum Disorders — ClinicalTrials.gov (U.S. National Library of Medicine)
- NCT01743651 (OS440-3002) — Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis — ClinicalTrials.gov (U.S. National Library of Medicine)
- NCT03290131 (OS440-3004) — A Study to Investigate the Safety and Effectiveness of Arbaclofen Extended-Release Tablets for Patients With MS — ClinicalTrials.gov (U.S. National Library of Medicine)
- NCT03319732 (OS440-3005) — A Study to Evaluate the Long-term Safety of Arbaclofen Extended-Release Tablets for Patients With Spasticity Due to MS — ClinicalTrials.gov (U.S. National Library of Medicine)
- NCT03682978 (AIMS2-CT-01) — Arbaclofen in Children and Adolescents With ASD — ClinicalTrials.gov (U.S. National Library of Medicine)
- NCT03887676 (ARB-05-2018) — Arbaclofen vs. Placebo in the Treatment of Children and Adolescents With ASD (ARBA) — ClinicalTrials.gov (U.S. National Library of Medicine)
- NCT05179577 (OS440-3006) — A Study to Investigate Arbaclofen ER Tablets for the Treatment of Spasticity in Patients With Multiple Sclerosis — ClinicalTrials.gov (U.S. National Library of Medicine)
- NCT07655115 (AIMS-2-CT2) — Single Dose Double-blind, Placebo-controlled Cross-over (SDDBPCCO) Shiftability Study, Will be Followed by a 10-week Open-label Study With Arbaclofen (4 Weeks of Titration and Then 6 Weeks of Active/Stable Treatment). The Effects of Arbaclofen on Target EEG and ERG Metrics Will be Associated With th — ClinicalTrials.gov (U.S. National Library of Medicine)
- Okuda DT, et al. Arbaclofen extended-release tablets for spasticity in multiple sclerosis: randomized, controlled clinical trial. Brain Commun 2022;4(6):fcac300 — Brain Communications (OUP) / PubMed
- Osmotica Pharmaceuticals plc Receives Complete Response Letter from U.S. FDA for Arbaclofen Extended Release Tablets (8-K Ex. 99.1, 2020-12-29) — Osmotica Pharmaceuticals plc / SEC EDGAR
- Parellada M, et al. Efficacy, safety, and tolerability of arbaclofen in autistic children and adolescents, the AIMS-2-TRIALS-CT1: a randomized, double-blind, placebo-controlled phase II trial. EClinicalMedicine 2026;92:103760 — EClinicalMedicine (Elsevier) / PubMed
- RVL Pharmaceuticals plc Form 10-K for fiscal year 2021 (filed 2022-03-30) — RVL Pharmaceuticals plc / SEC EDGAR
- RVL Pharmaceuticals plc Form 10-K for fiscal year 2022 (filed 2023-03-20) — RVL Pharmaceuticals plc / SEC EDGAR
- Trials of arbaclofen for autism yield mixed results (2023-05-05) — The Transmitter (Simons Foundation)
- Veenstra-VanderWeele J, et al. Arbaclofen in children and adolescents with autism spectrum disorder: a randomized, controlled, phase 2 trial. Neuropsychopharmacology 2017;42(7):1390-1398 — Neuropsychopharmacology / PubMed